Evidence mapPaperPMID 42463649Full record

ArticleNature communications2026

Multiomic profiling links L1 retrotransposition to genomic instability and ecDNA in bladder cancer.

Sophia J Pribus, Ivana Osredek, Jan Otoničar, Milena Simovic-Lorenz, Chiara Giovenino, Anne Rademacher, Sina Jasmin Wille, Cecilia Berzain Battioni, Michael Scherer, Sergio Manzano-Sanchez and 15 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Sophia J Pribus *European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.
Ivana Osredek *European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.
Jan Otoničar *Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
Milena Simovic-Lorenz *Division of Genome Instability and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-8835-6885
Chiara GioveninoFaculty of Biosciences, Heidelberg University, Heidelberg, Germany.ORCID 0000-0003-2041-4019
Anne RademacherDivision of Chromatin Networks, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany and Center for Quantitative Analysis of Molecular and Cellular Biosystems (BioQuant), Heidelberg University, Heidelberg, Germany.ORCID 0000-0003-3054-3121
Sina Jasmin WilleDivision of Chromatin Networks, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany and Center for Quantitative Analysis of Molecular and Cellular Biosystems (BioQuant), Heidelberg University, Heidelberg, Germany.ORCID 0009-0000-1254-7431
Cecilia Berzain BattioniDivision of Genome Instability and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Michael SchererDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-7990-6179
Sergio Manzano-SanchezDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0009-0006-5460-5824
Andreas KienzleDivision of Immunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0009-0008-4142-3196
Urja ParekhFaculty of Biosciences, Heidelberg University, Heidelberg, Germany.
Laura VillacortaEuropean Molecular Biology Laboratory, Genomics Core Facility, Heidelberg, Germany.
Vladimir BenesEuropean Molecular Biology Laboratory, Genomics Core Facility, Heidelberg, Germany.ORCID 0000-0002-0352-2547
Pooja SantSingle-cell Open Lab, German Cancer Research Center (DKFZ) and Bioquant, Heidelberg, Germany.ORCID 0000-0001-9301-3211
Jan-Philipp MallmSingle-cell Open Lab, German Cancer Research Center (DKFZ) and Bioquant, Heidelberg, Germany.ORCID 0000-0002-7059-4030
Karsten BrandMVZ of Pathology, Heidelberg, Germany.
Karsten RippeDivision of Chromatin Networks, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany and Center for Quantitative Analysis of Molecular and Cellular Biosystems (BioQuant), Heidelberg University, Heidelberg, Germany.ORCID 0000-0001-9951-9395
Angelika B RiemerDivision of Immunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-5865-0714
Holger SültmannDivision of Cancer Genome Research, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-5257-8600
Christoph PlassDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-2554-3952
Mladen StankovicDepartment of Urology, Salem Hospital, Academic Hospital, University of Heidelberg, Heidelberg, Germany.
Jan O KorbelEuropean Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany. jan.korbel@embl.org.ORCID 0000-0002-2798-3794
Tobias RauschEuropean Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany. rausch@embl.de.ORCID 0000-0001-5773-5620
Aurélie ErnstDivision of Genome Instability and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. a.ernst@dkfz.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer is frequent and highly recurrent. Despite recent advances, knowledge gaps remain in molecular mechanisms underlying disease progression. In this study, we apply integrated multi-omic analyses to a cohort of 48 bladder cancer patients to comprehensively profile genetic, epigenetic, transcriptomic, and spatial features. Combining cell-free DNA sequencing, long-read tumor DNA-sequencing, RNA-sequencing, and spatial transcriptomics, we explore molecular alterations driving bladder cancer. We find frequent somatic LINE-1 (L1) insertions, and show that these L1 insertions are active and occur early in bladder cancer development. We link somatic L1 insertion with downstream genomic rearrangements and chromosomal instability, including increased structural variant and extrachromosomal DNA (ecDNA) counts in patients with high L1 counts. We identify variable ecDNA enrichment across tissue architecture, with highest enrichment overlapping differential expression of APOBEC3B and immune response pathways. In summary, our results support a model whereby L1 retrotransposition triggers downstream genomic instability and viral mimicry response.

Indexed as

Genomic InstabilityLong Interspersed Nucleotide ElementsUrinary Bladder NeoplasmsExtrachromosomal DNAGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMultiomicsSpatial TranscriptomicsExtrachromosomal DNA

Identifiers

PMID42463649
PMCPMC13376730

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.